Talia Biran

Company: Oncolys BioPharma Inc.

Job title: President

Seminars:

Novel Strategy to Improve Immunotherapy & Radiotherapy Response in Gastroesophageal Cancers Utilizing Telomerase-based Oncolytic Virus 5:00 pm

Oncolys has developed a telomerase-based adenovirus OBP-301 (Suratadenoturev) that is conditionally replicating in cancer cells by introducing the human telomerase reverse transcriptase (hTERT) OBP-301 (Suratadenoturev) is currently being studied in registrational trials in Esophageal cancer in Japan with a target NDA submission by Q4 2024. It is also being studied in the United States in…Read more

day: Day One

Investor Panel Discussion & Q&A: Bridging the Gap Between Pharma, Biotech & Investors 12:00 pm

This panel discussion will bring together experts from the investment community, pharma, and biotech sectors to facilitate the growth and development of the field. This panel will provide a platform for these stakeholders to connect, share perspectives, and explore potential partnerships. Take part in this deep-dive panel discussion and hear from the leading minds as…Read more

day: Day One